Tuesday, March 02, 2021 12:40:16 PM
Here's a small sampling of the dozens of PUMP-and-DUMP cycles this worthless POS has ran over the past 16 years.
Always lower highs and lower lows. This current one is just one of many.
Watch and learn:
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
November, 2005
https://www.businesswire.com/news/home/20051107005498/en/NanoViricides-Reports-Initial-Safety-Results-Anti-Influenza-Bird
Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc. September, 2007
https://www.businesswire.com/news/home/20070904005487/en/Influenza-Bird-Flu-Therapeutics-Moving-Rapidly-NanoViricides
NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs January, 2008.
https://www.businesswire.com/news/home/20080122005644/en/NanoViricides-Develop-Bird-Flu-Influenza-Drugs
NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever June, 2010
https://www.biospace.com/article/releases/nanoviricides-inc-release-anti-dengue-nanoviricides-achieve-significant-protection-in-initial-in-vivo-studies-on-dengue-hemorrhagic-fever-/
NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency November, 2013
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20European%20Medicines%20Agency%20(EMA).html
NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference June, 2014
https://www.businesswire.com/news/home/20140714005478/en/NanoViricides-President-Dr.-Diwan-Presented-FluCide-Data
NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates September, 2014
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model April 2015
https://www.biospace.com/article/releases/nanoviricides-inc-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-/
NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruse June 2016
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology October, 2017
http://www.nanoviricides.com/press%20releases/2017/NanoViricides%20to%20Present%20Results%20On%20Successful%20Treatment%20Of%20Herpes-Induced%20Acute%20Retinal%20Necrosis%20at%20the%20Annual%20Meeting.html
NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials May,2018
https://www.biospace.com/article/releases/nanoviricides-provides-update-says-company-is-stable-and-is-moving-steadily-towards-clinical-trials/?s=86
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials Feb, 2019
https://www.accesswire.com/567044/NanoViricides-Files-Quarterly-Report-for-Period-Ending-September-30-2019--HerpeCide-Drug-Candidate-IND-Enabling-Studies-Update-Progressing-Towards-Clinical-Trials
NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses. May 12, 2020
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/82433957/nanoviricides-develops-highly-effective-broad-spec
Always lower highs and lower lows. This current one is just one of many.
Watch and learn:
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
November, 2005
https://www.businesswire.com/news/home/20051107005498/en/NanoViricides-Reports-Initial-Safety-Results-Anti-Influenza-Bird
Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc. September, 2007
https://www.businesswire.com/news/home/20070904005487/en/Influenza-Bird-Flu-Therapeutics-Moving-Rapidly-NanoViricides
NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs January, 2008.
https://www.businesswire.com/news/home/20080122005644/en/NanoViricides-Develop-Bird-Flu-Influenza-Drugs
NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever June, 2010
https://www.biospace.com/article/releases/nanoviricides-inc-release-anti-dengue-nanoviricides-achieve-significant-protection-in-initial-in-vivo-studies-on-dengue-hemorrhagic-fever-/
NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency November, 2013
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20European%20Medicines%20Agency%20(EMA).html
NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference June, 2014
https://www.businesswire.com/news/home/20140714005478/en/NanoViricides-President-Dr.-Diwan-Presented-FluCide-Data
NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates September, 2014
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model April 2015
https://www.biospace.com/article/releases/nanoviricides-inc-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-/
NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruse June 2016
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology October, 2017
http://www.nanoviricides.com/press%20releases/2017/NanoViricides%20to%20Present%20Results%20On%20Successful%20Treatment%20Of%20Herpes-Induced%20Acute%20Retinal%20Necrosis%20at%20the%20Annual%20Meeting.html
NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials May,2018
https://www.biospace.com/article/releases/nanoviricides-provides-update-says-company-is-stable-and-is-moving-steadily-towards-clinical-trials/?s=86
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials Feb, 2019
https://www.accesswire.com/567044/NanoViricides-Files-Quarterly-Report-for-Period-Ending-September-30-2019--HerpeCide-Drug-Candidate-IND-Enabling-Studies-Update-Progressing-Towards-Clinical-Trials
NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses. May 12, 2020
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/82433957/nanoviricides-develops-highly-effective-broad-spec
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
